BioXcel Therapeutics, Inc.'s first potential drug candidate – a sublingual thin film of dexmedetomidine (BXCL501) – met the primary endpoints of two Phase III clinical trials, resulting in rapid and durable reductions in agitation in schizophrenia and bipolar disorder. The company announced the positive data from the SERENITY I and SERENITY II trials on 20 July and said it was turning its focus to regulatory filings and commercialization.
The company is targeting a regulatory filing in the first quarter of 2021 and investors applauded the news